** Shares of Orthocell OCC.AX rise 14.3% to A$1.435, set for strongest session since January 22, if gains hold
** The biotech firm applies for a regulatory approval to begin sales of its nerve repair product Remplir in Hong Kong
** Co expects to receive approval by Q4 CY2025
** About 2.1 million shares change hands, 1.4x times the 30-day average of 1.5 million
** Stock up 5.2% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。